{"filing":{"accession_number":"0001628280-26-042396","cik":"0001636651","ticker":"OVID","company_name":"Ovid Therapeutics Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"ovid-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1636651/000162828026042396/ovid-20260611.htm"},"events":[{"id":5493,"run_id":4815,"accession_number":"0001628280-26-042396","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Ovid Therapeutics' annual meeting of stockholders held on June 10, 2026. The filing presents voting results for three proposals: (1) election of director Jeremy M. Levin (87.2M votes for, 8.5M withheld), (2) advisory approval of named executive officer compensation (84.5M for, 8.9M against), and (3) ratification of KPMG LLP as auditor (130.8M for, 32.5K against). These are routine annual meeting matters that materially inform shareholders about governance and management approval.","company_name":"Ovid Therapeutics Inc.","ticker":"OVID","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6137,"accession_number":"0001628280-26-042396","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Ovid Therapeutics' annual meeting of stockholders held on June 10, 2026. The filing presents voting results for three proposals: (1) election of director Jeremy M. Levin (87.2M votes for, 8.5M withheld), (2) advisory approval of named executive officer compensation (84.5M for, 8.9M against), and (3) ratification of KPMG LLP as auditor (130.8M for, 32.5K against). These are routine annual meeting matters that materially inform shareholders about governance and management approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T13:04:06.222209+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6137,"accession_number":"0001628280-26-042396","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Ovid Therapeutics' annual meeting of stockholders held on June 10, 2026. The filing presents voting results for three proposals: (1) election of director Jeremy M. Levin (87.2M votes for, 8.5M withheld), (2) advisory approval of named executive officer compensation (84.5M for, 8.9M against), and (3) ratification of KPMG LLP as auditor (130.8M for, 32.5K against). These are routine annual meeting matters that materially inform shareholders about governance and management approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T13:04:06.222209+00:00","company_name":"Ovid Therapeutics Inc.","ticker":"OVID","filing_date":"2026-06-11"}]}